spacer
home > ebr > summer 2017 > acting up
PUBLICATIONS
European Biopharmaceutical Review

Acting Up

On January 4, 1983, President Reagan signed the Orphan Drug Act (ODA) into law with the goal of providing financial and marketing incentives so that private pharmaceutical companies would develop more therapeutics for rare diseases. The benefits offered by the ODA include seven years of marketing exclusivity upon approval, tax credits worth 50% of the cost of human clinical trials and federal research grants to fund the development of orphan drugs.

Today, critics question whether the ODA is being used appropriately by firms. Most of this discussion is centred around the ‘orphan subset’ – a subset of a relatively common disease that a narrowly-targeted therapy might be developed for to qualify as an orphan drug and reap the ODA’s protections and benefits. In February 2017, Senator Chuck Grassley opened an inquiry into potential abuses of ODA by drug sponsor; this inquiry is likely to investigate the practice of ‘salami-slicing’ and how this may contribute to high prices of orphan drugs.

Salami-Slicing


This practice is defined as “artificially subdividing diseases to create subgroups of patients that fall under the orphan drug prevalence threshold”.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Matthew Weinberg is Chief Executive Officer at The Weinberg Group. He guides all strategic issues with management client efforts, emphasising the provision of tactical and operational assistance to technically-oriented entities in areas including R&D, regulatory affairs and quality assurance. Matthew’s assignments have involved development of new products, testimony of the management and economics of scientific enterprises, contract issues and product advancement.

Emily Krulewitz is a Consultant at The Weinberg Group. Her work involves issues related to the development and regulation of therapeutics, medical devices, tobacco products and foods. Emily has experience in the preparation, coordination and compilation of regulatory submissions as well as responding to various legislative challenges through the development of technical reports. She received a bachelor’s degree in chemistry and integrated arts from Northwestern University, US, and a master’s degree in biotechnology from Johns Hopkins University, US.

spacer
Matthew Weinberg
spacer
spacer
spacer
Emily Krulewitz
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Aptar Pharma to Highlight Key Innovations Addressing Today’s Megatrends in Drug Delivery at CPHI Worldwide in Frankfurt, Germany


More info >>

White Papers

Crossing the Blood Brain Barrier (BBB): Which Route to Take?

Aptar Pharma

Aptar Pharma recently hosted an expert panel/roundtable on the various approaches to treating central nervous system (CNS) diseases. This international scientific forum was held in Paris, France on December 5th, 2014. The roundtable was organized to explore and exchange views on the challenges, approaches and opportunities that exist with regard to effectively crossing the blood brain barrier (BBB) and successfully treating a host of CNS diseases.
More info >>

 
Industry Events

Temperature Controlled Logistics 2018

29 January - 1 February 2018, Twickenham Stadium, London

Each January for the past 16 years, more than 400 senior supply chain, logistics, storage, regulation and quality experts from the pharmaceutical industry have gathered at the TCL Forum for the largest, longest running and most comprehensive cold chain and ambient logistics conference in Europe.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement